New Triple-Drug cocktail shows promise for Tough-to-Treat recurrent cancers

NCT ID NCT04781088

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests a new combination of three FDA-approved drugs (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the triple therapy shrinks tumors more effectively than current options, while monitoring side effects. About 38 participants will receive the drugs to evaluate safety and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial carcinoma endometrium neoplasm fallopian tube carcinoma fallopian tube neoplasm ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Allegheny Health Network

    Pittsburgh, Pennsylvania, 15224, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States